Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Subcutaneous ICD Matches Standard ICD In Controlled Trial

This article was originally published in The Gray Sheet

Executive Summary

Short-term results in a study of Boston Scientific's S-ICD device show promise, but also point to room for improvement.

You may also be interested in...



Subcutaneous ICD Matches Conventional Defibrillators In Registry

Boston Scientific’s S-ICD subcutaneous implantable cardioverter defibrillator performed well in the EFFORTLESS registry, with clinical event rates and inappropriate shock rates similar to those reported for conventional ICDs in a real-world context.

Percutaneous Intravascular Defibrillator Could Avert Common ICD Complications

A percutaneous intravascular cardioverter-defibrillator matched a conventional ICD in a randomized comparison of defibrillation thresholds. The authors of the study believe the PICD could reduce many of the complications associated with conventional defibrillators.

New Products In Brief

Recent new product launches and approvals include Boston Scientific’s novel S-ICD subcutaneous implantable cardioverter defibrillator, Globus Medical’s Secure-C artificial cervical disc and ConforMIS’ next-generation iTotal G2 total knee replacement.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT032468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel